T. Rowe Price Investment Management’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $582M | Buy |
17,602,440
+7,647,189
| +77% | +$253M | 0.37% | 75 |
|
|
2025
Q1 | $400M | Sell |
9,955,251
-796,872
| -7% | -$32M | 0.26% | 109 |
|
|
2024
Q4 | $506M | Buy |
10,752,123
+1,062,136
| +11% | +$50M | 0.31% | 92 |
|
|
2024
Q3 | $512M | Buy |
9,689,987
+1,551,310
| +19% | +$81.9M | 0.31% | 88 |
|
|
2024
Q2 | $441M | Buy |
8,138,677
+3,017,088
| +59% | +$163M | 0.28% | 94 |
|
|
2024
Q1 | $359M | Buy |
5,121,589
+2,892,104
| +130% | +$203M | 0.22% | 117 |
|
|
2023
Q4 | $186M | Buy |
2,229,485
+413,299
| +23% | +$34.5M | 0.12% | 195 |
|
|
2023
Q3 | $53.5M | Buy |
1,816,186
+11,870
| +0.7% | +$350K | 0.04% | 354 |
|
|
2023
Q2 | $58.9M | Buy |
1,804,316
+286,254
| +19% | +$9.34M | 0.04% | 353 |
|
|
2023
Q1 | $53.4M | Buy |
1,518,062
+1,054,416
| +227% | +$37.1M | 0.04% | 357 |
|
|
2022
Q4 | $21.2M | Buy |
+463,646
| New | +$21.2M | 0.02% | 451 |
|